|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.71|
|Dividend & Yield||1.03 (3.24%)|
|1y Target Est||N/A|
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
In 2016, Roche Holding AG sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the U.S. Food and Drug Administration approved what’s expected to be a less-expensive version.